Developing a new drug or medical device takes many years and large amounts of capital, and most of the value arrives late, after approval and launch. The financing tools available to innovators are often poorly matched to that profile. Non-dilutive capital, in its several forms, exists to close the gap.
This note explains the main instruments, how they are structured, what protects each side of a transaction, and why the middle of the market has fewer options than it should. It describes the sector and how this kind of capital works. It does not describe any transaction, fund or offering.
A financing problem shaped by time
A life sciences product spends years consuming capital before it produces any revenue. Discovery, preclinical work, clinical trials, manufacturing scale-up and regulatory review all come first. Even after approval, sales typically build over several years as physicians adopt the product and payers settle coverage.
The result is a long period of heavy spending followed by a long period of revenue, with a binary regulatory event in between. Most financing instruments were not designed for that shape. They assume steady operating cash flow, tangible collateral or a near-term exit, and many life sciences companies have none of the three at the moment they need capital most.
The problem with the usual tools
Equity is the default source of funding for life sciences companies, but it is dilutive, and when valuations are volatile, raising equity at the wrong moment can be very expensive for existing shareholders. A company that sells shares after a market downturn may give up a large share of its future for capital it needs only to reach the next milestone.
Conventional bank lending is often unavailable, because banks struggle to underwrite assets such as patents, clinical data and regulatory approvals. Those assets can be very valuable, but their value depends on scientific, regulatory and commercial judgments that sit outside a typical credit process.
Universities and research institutions, meanwhile, may hold long-dated royalty interests they cannot easily value or sell. The royalty may be one of the most valuable assets the institution owns, yet it pays out slowly and depends on decisions made by a company the institution does not control.
Three non-dilutive instruments
- Royalty monetization: the holder of an existing royalty on an approved or late-stage product sells all or part of it for an upfront payment.
- Synthetic royalty: a company that owns a product sells a share of that product's future net sales in exchange for capital, without giving up equity.
- Structured credit: loans or revenue-linked financing designed around the cash flows of approved products rather than conventional corporate collateral.
Each instrument suits a different holder and a different moment. A royalty monetization is usually a transaction with a royalty owner, such as a university, an inventor or a company that out-licensed a product. A synthetic royalty creates a new royalty where none existed, carved out of a product the company still owns and sells. Structured credit looks more like a loan, but its size, repayment and covenants are built around product revenue rather than general corporate cash flow.
Returns are driven by the net sales of approved products, not by corporate profitability.
That distinction matters in practice. Returns are driven by the net sales of approved products, not by corporate profitability. A company can be losing money overall, because it is funding a pipeline, while one approved product generates steady sales. Product-linked capital can look at that product on its own merits.
How a synthetic royalty works
Consider a hypothetical commercial-stage company with one approved product and a second product in late-stage trials. It needs capital to fund the second program and expand the sales force for the first. Its share price has fallen with the broader sector, and an equity raise would be heavily dilutive.
In a synthetic royalty, the company might agree to pay a percentage of the first product's future net sales to a financier in exchange for capital today. The company keeps ownership of the product and the business. Its shareholders keep their equity. The financier's payments rise and fall with the product's sales.
The terms usually address several practical questions. What counts as net sales, and which deductions are allowed? Does the percentage decline as sales pass certain thresholds? Does the obligation end when total payments reach a defined cap, or on a fixed date? What happens if the company is acquired or the product is sold? Each answer shifts risk between the parties, which is why the documents matter as much as the headline percentage.
Structural protections for both sides
Good non-dilutive transactions are built with explicit downside cases in mind. The financier is taking product risk, and the company is giving up part of a future revenue stream. Structure is how both sides set limits on what they are agreeing to.
- Caps: a ceiling on total payments, after which the royalty or revenue interest ends, so the company knows the most it can owe.
- Step-ups and step-downs: payment rates that change if sales fall short of, or exceed, agreed levels or dates.
- Puts and calls: rights to require or allow repayment on specified events, such as a change of control or a material adverse development.
- Covenants: commitments about how the product will be supported, how sales will be reported and what the company may not do with the underlying asset.
- Milestone-contingent funding: capital released in stages as regulatory or commercial milestones are reached, rather than all at once.
These features are not ornaments. A cap protects the company from paying indefinitely on a product that does far better than expected. A step-up or milestone condition protects the financier if a launch is slower than planned. Staged funding lets both sides commit to a larger relationship without betting everything on the first forecast.
What companies should ask
A company considering non-dilutive capital should compare offers on more than the amount and the rate. The shape of the obligation over time, and how it behaves in a bad year, often matters more.
- How is net sales defined, and does it match how the company already reports revenue?
- What is the total cost under a weak case, a base case and a strong case, not only the base case?
- What happens on a change of control, and could the terms discourage a future acquirer?
- What reporting, audit and consent rights does the financier receive, and how burdensome are they?
- Does the financier understand the science, the regulatory path and the commercial plan, or will every question become a negotiation?
Common mistakes
The most frequent mistake is treating non-dilutive capital as free because it does not dilute. It has a cost, and that cost depends on how the product performs. A company should model the obligation under realistic scenarios and confirm it can live with the result.
A second mistake is overlooking interactions with other agreements. Existing licenses, credit facilities and partnership agreements may restrict what a company can sell or pledge. Discovering a conflict late can delay a transaction or force a costly renegotiation.
A third is choosing a counterparty on price alone. Royalty and revenue interest agreements can last many years. A financier who understands the product and responds sensibly to unexpected events is worth a great deal over that period.
Why the middle market is underserved
The largest royalty investors tend to focus on large transactions tied to major products. That leaves a gap for smaller companies, smaller products and university royalty holders whose needs are meaningful to them but too small to attract the largest players.
The underwriting work for a smaller transaction is not much less than for a large one, which is part of why fewer investors pursue it.
The underwriting work for a smaller transaction is not much less than for a large one, which is part of why fewer investors pursue it. Evaluating the science, the clinical data, the patents, the regulatory position and the commercial outlook takes the same disciplines whether the transaction is large or small. For a firm built around very large transactions, that effort is hard to justify on a smaller one.
Meanwhile, the need in the middle market is real. Specialty products, rare disease therapies, diagnostics and medical devices can serve important patient populations with sales that are significant but not enormous. Their owners face the same mismatch between dilutive equity and unavailable bank credit as larger companies do, with fewer alternatives.
How Crucible is being built
UpManagement Crucible is being built to provide non-dilutive capital to biopharmaceutical and medical technology companies, universities and royalty holders through royalty monetizations, synthetic royalties and revenue interest financings, and structured credit. It is an investor and financier, not a drug developer.
Its approach centers on integrated diligence, covering science, clinical data, FDA and CMS regulation, patents and exclusivity, and commercial and pricing dynamics, and on structures with explicit downside cases. As an UpManagement company, Crucible draws on a shared platform for finance, compliance, legal, technology and operations, so its own team can concentrate on understanding products and the people who hold them.
Crucible is a platform in formation. Its investment adviser registration and other approvals are not yet in place.
This article is for general information only. It is not an offer to sell, or a solicitation of an offer to buy, any security or investment product, and nothing on this site markets any investment.
Published by UpManagement. This article is general information about the sectors in which the UpManagement companies operate. It is not legal, tax, investment or compliance advice, and it is not an offer to sell or a solicitation of an offer to buy any security. Where a company is described as a platform in formation, its approvals are not yet in place.
